Alison Clough, acting CEO of the Association of the British Pharmaceutical Industry (ABPI), responds to recent reports in the media on the price of medicines in the UK.
Alison said: "The medicines developed by our member companies make a huge contribution to the health and wealth of our nation.
"The ABPI is responsible for negotiating with the Government, on behalf of the branded pharmaceutical industry, for the pricing scheme for medicines in the UK. Under the Pharmaceutical Price Regulation Scheme (PPRS), the pharmaceutical industry contributes and pays for growth in branded medicines used in the NHS. This year alone our members will pay back nearly £1billion in payments to the Government. Overall we expect to pay back £4billion over the five years of the current scheme.
"Industry did this deal with the Government to provide breathing space for an NHS under considerable financial pressure to enable patients' access to newer medicines. The UK already lags behind the rest of Europe in investing in medicines and the NHS in England currently spends just under 10p in every £1 on branded medicines, which represents just under 10% of the overall NHS budget. Moreover, recent growth figures for branded medicines in the UK have been going down, raising concerns that NHS patients in the UK are losing out when it comes to accessing the latest medicines.
"We passionately believe that NHS patients should be able to receive the medicines their clinicians believe they will benefit from and we are committed to working with the NHS and the Government to achieve this."
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.
ABPI Press OfficeTelephone: +44 (0) 20 7747 1410 or +44 (0) 20 7747 1441Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: firstname.lastname@example.org